{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"A TE-ADA evaluable participant is considered TE-ADA positive if they have at least one post-baseline ADA titer that is a 4-fold or greater increase from their baseline titer (treatment-boosted); alternatively, if the baseline ADA result is Not Present, the participant is considered TE-ADA positive if there is at least one post-baseline ADA result that is Present with a titer greater than or equal to 1:20 (treatment-induced).","groups":[{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Ramucirumab administered intravenously at a dose of 12 mg/kg as a one-hour infusion on days 1 and 15.\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG000","title":"Ramucirumab + Cyclophosphamide + Vinorelbine"},{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG001","title":"Cyclophosphamide + Vinorelbine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants who received at least one dose of study drug and had at least one non-missing baseline, post baseline ADA value.","reportingStatus":"POSTED","timeFrame":"Baseline Up to 23 months","title":"Number of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}